

FOR IMMEDIATE RELEASE

CONTACT:

Michele Rozen
Pure Communications
617-730-8284

Catabasis Pharmaceuticals to Present at Upcoming Industry and Investment Conferences

CAMBRIDGE, Mass. – November 22, 2011 – [Catabasis Pharmaceuticals](#), a biopharmaceutical company leveraging the therapeutic potential of omega-3 fatty acids for the treatment of inflammatory and metabolic diseases, today announced that Catabasis management will present at upcoming industry and investment conferences.

- Michael Jirousek, Ph.D., chief scientific officer and co-founder of Catabasis, will present at [Windhover Information's 6th Annual Therapeutic Area Partnerships](#), being held Nov. 30-Dec. 2 at the Westin Copley Place in Boston. Dr. Jirousek will give a presentation on Catabasis and the company's CAT-1000 program at 11:20 a.m. on Thursday, Dec. 1.

CAT-1000 targets inflammation, which has been shown to be an underlying cause of many chronic diseases. Catabasis' CAT-1000 program was selected by Windhover, Healogix and Cobbs Creek Healthcare as one of the Top 10 Most Interesting Immunology/Autoimmune Projects to Watch. The company recently initiated a clinical trial for its lead product candidate, CAT-1004, which is in development to treat type 2 diabetes.

- Jill C. Milne, Ph.D., chief executive officer and co-founder of Catabasis, will present at the [Oppenheimer 22nd Annual Healthcare Conference](#), being held Dec. 13-14 at the Waldorf Astoria in New York City. Dr. Milne will give a presentation at 1:15 p.m. on Wednesday, Dec. 14.

Catabasis' presentation will be part of the private company track. This conference presents a core group of public and private companies who are leaders and pioneers in the pharmaceutical, biotechnology, medical device, healthcare facility, lifescience tools and diagnostics, health technology and distribution, provider and service industries.

About Catabasis

Catabasis is a clinically staged company dedicated to the discovery and development of innovative, effective and safe medicines to treat inflammatory and metabolic diseases. The company has assembled a team of passionate and experienced scientists who are committed to improving the lives of patients. Catabasis has developed a pipeline of molecules that amplify the beneficial effects of omega-3 fatty acids to target the underlying etiologies of a spectrum of complex human diseases. Catabasis' approach dramatically enhances the therapeutic potential of docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA), two essential fatty acids found

in fish oil, by improving the delivery, potency and efficacy. The company was founded in 2008 and is headquartered in Cambridge, Mass. Please visit www.catabasispharma.com for more information.

###